top of page
post-aspot-bg.jpg

BrainsWay to Report Fourth Quarter and Full Year 2020 Financial Results on March 25, 2021


CRESSKILL, N.J., March 11, 2020 – BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today announced that it will report its fourth quarter and full year 2020 financial results as well as operational highlights after the close of the financial markets on Wednesday, March 24, 2021. The Company will host a conference call and webcast on Thursday, March 25, 2021 at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.


Conference Call Dial-In & Webcast Information:

Date: Thursday, March 25, 2021

Time: 8:30 AM Eastern TimeUnited States:877-407-3982Israel:1 809 406 247International:201-493-6780Conference ID:13717245Webcast:http://public.viavid.com/index.php?id=143838


The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, https://investors.brainsway.com/events-and-presentations/event-calendar. Please access the Company’s website at least 10 minutes ahead of the conference call to register.


About BrainsWay BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology. The Company received marketing authorization from the U.S. Food and Drug Administration (FDA) for its products for a variety of patient populations, including in 2013 for patients with major depressive disorder (MDD), in 2018 for patients with obsessive-compulsive disorder (OCD), and in 2020 for patients with smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. To learn more, please visit www.brainsway.com.


Contacts: BrainsWay: Hadar Levy SVP and General Manager HadarL@brainsway.com

Investors: Bob Yedid LifeSci Advisors 646-597-6989 Bob@LifeSciAdvisors.com

Comments


bottom of page